Jasper Therapeutics, Inc. (JSPR)
JSPR Stock Price Chart
Explore Jasper Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze JSPR price movements and trends.
JSPR Company Profile
Discover essential business fundamentals and corporate details for Jasper Therapeutics, Inc. (JSPR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Jan 2020
Employees
22.00
Website
https://jaspertx.comCEO
Jeetinder Singh Mahal
Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
JSPR Financial Timeline
Browse a chronological timeline of Jasper Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.38.
Earnings released on 14 May 2026
EPS came in at -$0.06 surpassing the estimated -$0.46 by +86.70%.
Earnings released on 30 Mar 2026
EPS came in at -$0.32 surpassing the estimated -$0.79 by +59.49%.
Earnings released on 10 Nov 2025
EPS came in at -$1.13 falling short of the estimated -$1.01 by -11.88%.
Earnings released on 13 Aug 2025
EPS came in at -$1.74 falling short of the estimated -$1.20 by -45.00%.
Earnings released on 12 May 2025
EPS came in at -$1.41 falling short of the estimated -$1.17 by -20.51%.
Earnings released on 27 Feb 2025
EPS came in at -$1.62 falling short of the estimated -$1.27 by -27.56%, while revenue for the quarter reached $1.17m .
Earnings released on 7 Nov 2024
EPS came in at -$1.24 falling short of the estimated -$1.09 by -13.76%.
Earnings released on 13 Aug 2024
EPS came in at -$0.97 surpassing the estimated -$1.09 by +11.01%.
Earnings released on 14 May 2024
EPS came in at -$1.03 surpassing the estimated -$1.26 by +18.25%.
Earnings released on 4 Mar 2024
EPS came in at -$1.50 surpassing the estimated -$1.65 by +9.09%, while revenue for the quarter reached $2.05m .
Stock split effective on 4 Jan 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 9 Nov 2023
EPS came in at -$1.60 falling short of the estimated -$1.50 by -6.67%.
Earnings released on 11 Aug 2023
EPS came in at -$1.50 falling short of the estimated -$1.30 by -15.38%.
Earnings released on 12 May 2023
EPS came in at -$1.60 falling short of the estimated -$1.50 by -6.67%.
Earnings released on 8 Mar 2023
EPS came in at -$3.60 surpassing the estimated -$3.70 by +2.70%.
Earnings released on 10 Nov 2022
EPS came in at -$3.20 surpassing the estimated -$3.50 by +8.57%.
Earnings released on 12 Aug 2022
EPS came in at -$2.90 matching the estimated -$2.90.
Earnings released on 12 May 2022
EPS came in at -$3.50 surpassing the estimated -$3.60 by +2.78%.
Earnings released on 18 Mar 2022
EPS came in at -$0.79 falling short of the estimated -$0.34 by -132.35%.
Earnings released on 12 Nov 2021
EPS came in at -$0.69 falling short of the estimated -$0.28 by -146.43%.
Earnings released on 16 Aug 2021
EPS came in at -$0.84 .
JSPR Stock Performance
Access detailed JSPR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
